Research sheds light on what causes severe inflammatory bowel disease.

Published Date: 26 Apr 2023

Researchers from Cedars-Sinai have discovered a genetic variation that raises the risk of perianal Crohn's disease, the most crippling form of the condition, in susceptible individuals.

Read Full News

Latest News

ANTHEM-UC: Icotrokinra Shows Sustained Efficacy in Moderate-to-Severe Ulcerative Colitis, With Vipul Jairath, MBChB, DPhil Vipul Jaraith, MBChB, DPhil

ANTHEM-UC study findings presented at ACG show efficacy, durability and safety of icotrokinra in adults with moderate-to-severe ulcerative colitis.

Joshua Wechsler, MD, on dupilumab's sustained efficacy in pediatric patients with EoE Joshua Wechsler, MD, MSCI

Dupilumab maintained histologic and endoscopic improvements across all pediatric age groups with EoE, according to Joshua Wechsler, MD.

NASPGHAN: Best Practices for Celiac Disease Follow-up with Dale Lee, MD Dale Lee, MD

Dale Lee, MD, told HCPLive that regular monitoring and potential psychosocial support are important to help children with celiac disease maintain a gluten-free diet.

Julie Khlevner, MD, AGAF, Reacts to the FDA Approval of Linaclotide for Pediatric IBS-C Julie Khlevner, MD, AGAF

Julie Khlevner, MD, AGAF, highlights that FDA approval of linaclotide provides the first pharmacologic therapy for pediatric IBS-C.

Rimegepant Linked to Increased Rectal Compliance, Reduced Rectal Sensation in IBS, With Ayah Matar, MD Ayah Matar, MD

Late-breaking ACG 2025 data link rimegepant to increased rectal compliance and reduced rectal sensation in IBS without constipation.

Tegoprazan NDA Seeks FDA Approval for 3 GERD Indications

Tegoprazan NDA Seeks FDA Approval for 3 GERD Indications

Todays Updates

FDA Updates Label for Reduced Osteoarthritis Risk With BEAR Implant Over ACL Reconstruction Victoria Johnson

FDA approves a label update for the BEAR implant, which was previously approved in 2020.

AI Scribes Reduce Physician Burnout Within 30 Days, With Lee Schwamm, MD Lee Schwamm, MD

Physicians experience significant challenges with increasing administrative burdens impacting patient care. Study shows AI scribes can help reduce burnout.

NeurologyLive® Friday 5 — January 23, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 23, 2026.

Evaluating Durable Dysphagia Outcomes in OPMD: Insights From Early BB-301 Clinical Data Marco Meglio

Jerel Banks, MD, PhD, chief executive officer of Benitec Biopharma, reviews early phase 1b/2a clinical signals, mechanism, and next steps for BB-301 in oculopharyngeal muscular dystrophy.

Phase 1/2a Findings Lend Support for BB-301 in Oculopharyngeal Muscular Dystrophy Marco Meglio

Benitec Biopharma reveals promising results for BB-301, a gene therapy showing significant improvements in swallowing function for OPMD patients.

NeurologyLive® Brain Games: January 25, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the ALS Treatment pathways!

GLP-1 Discontinuation Results in Significant Weight Regain, With Michael Weintraub, MD

GLP-1 Discontinuation Results in Significant Weight Regain, With Michael Weintraub, MD

Todays Updates

FDA Updates Label for Reduced Osteoarthritis Risk With BEAR Implant Over ACL Reconstruction Victoria Johnson

FDA approves a label update for the BEAR implant, which was previously approved in 2020.

AI Scribes Reduce Physician Burnout Within 30 Days, With Lee Schwamm, MD Lee Schwamm, MD

Physicians experience significant challenges with increasing administrative burdens impacting patient care. Study shows AI scribes can help reduce burnout.

NeurologyLive® Friday 5 — January 23, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 23, 2026.

Evaluating Durable Dysphagia Outcomes in OPMD: Insights From Early BB-301 Clinical Data Marco Meglio

Jerel Banks, MD, PhD, chief executive officer of Benitec Biopharma, reviews early phase 1b/2a clinical signals, mechanism, and next steps for BB-301 in oculopharyngeal muscular dystrophy.

Phase 1/2a Findings Lend Support for BB-301 in Oculopharyngeal Muscular Dystrophy Marco Meglio

Benitec Biopharma reveals promising results for BB-301, a gene therapy showing significant improvements in swallowing function for OPMD patients.

NeurologyLive® Brain Games: January 25, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the ALS Treatment pathways!

GLP-1 Discontinuation Results in Significant Weight Regain, With Michael Weintraub, MD

GLP-1 Discontinuation Results in Significant Weight Regain, With Michael Weintraub, MD

Latest News

ANTHEM-UC study findings presented at ACG show efficacy, durability and safety of icotrokinra in adults with moderate-to-severe ulcerative colitis.

Dupilumab maintained histologic and endoscopic improvements across all pediatric age groups with EoE, according to Joshua Wechsler, MD.

Dale Lee, MD, told HCPLive that regular monitoring and potential psychosocial support are important to help children with celiac disease maintain a gluten-free diet.

Julie Khlevner, MD, AGAF, highlights that FDA approval of linaclotide provides the first pharmacologic therapy for pediatric IBS-C.

Late-breaking ACG 2025 data link rimegepant to increased rectal compliance and reduced rectal sensation in IBS without constipation.

Tegoprazan NDA Seeks FDA Approval for 3 GERD Indications

News All Time

Predicting Teduglutide Treatment Response for Pediatric SBS-IF, With Valeria Cohran, MD

Predicting Teduglutide Treatment Response for Pediatric SBS-IF, With Valeria Cohran, MD

Microbiota Restoration Therapy: A New Era in C. difficile Management, With Paul Feuerstadt, MD Paul Feuerstadt, MD

FDA-approved RBL shows 95% success and sustained microbiome restoration in recurrent C. difficile.

H. pylori Geographical Prevalence and NASPGHAN/ESPGHAN Guidelines, With Silvana Bonilla, MD Silvana Bonilla, MD

Multicenter data presented by Silvana Bonilla, MD, at NASPGHAN 2025 highlight regional variation in pediatric H. pylori prevalence and support selective biopsy practices guided by clinical suspicion.

5 Gastroenterology Headlines You Missed in November 2025

5 Gastroenterology Headlines You Missed in November 2025

Geographic Disparities in GI Specialist Availability Suggest Limited Access to Care

Geographic Disparities in GI Specialist Availability Suggest Limited Access to Care

AI Tools Fall Short for Dietary Recommendations for Managing IBS

AI Tools Fall Short for Dietary Recommendations for Managing IBS

AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies

AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies

Reducing Diagnostic Delays and Improving Follow-Up Care for EoE, With Rosa Yu, MD

Reducing Diagnostic Delays and Improving Follow-Up Care for EoE, With Rosa Yu, MD

The HCPFive: Top News for Healthcare Providers from the Week of 10/05 HCPLive Editorial Staff

Stay updated with the latest healthcare breakthroughs, including FDA approvals and clinical trial readouts, in this week's essential news roundup.

Small Intestine Dilation Links to Food-Protein-Induced Enterocolitis Syndrome Chelsie Derman

A recent study reveals that small intestinal dilation significantly contributes to abdominal symptoms in adults with Food-Protein-Induced Enterocolitis Syndrome (FPIES).

LUCENT-3: Mirikizumab (Omvoh) Shows Sustained Benefit in Ulcerative Colitis Through 4 Years Abigail Brooks, MA

LUCENT-3 open-label extension study data establish mirikizumab-mrkz (Omvoh) as the first and only IL-23p19 to show sustained long-term outcomes in UC through 4 years.

HCPLive 5 Stories in Under 5: Week of 10/05 Victoria Johnson

An audio recap of the top 5 stories in healthcare news from the week of 10/5-10/11.

FDA Approves Updated Indication for Upadacitinib (Rinvoq) in IBD Abigail Brooks, MA

The decision updates the indication statements for ulcerative colitis and Crohn’s disease to allow use in patients who have received ≥ 1 approved systemic therapy.

Empirical Donor Selection, 2-Dose Capsule FMT Regimen Improve C Diff Cure Rates Abigail Brooks, MA

Findings from the quality improvement study provide real-world data supporting empirical donor exclusion and multiple-dose capsule FMT to increase CDI cure rates.

Conference Preview: American College of Gastroenterology’s 2025 Annual Scientific Meeting Abigail Brooks, MA

View slated expert interviews and 6 clinical GI, hepatology, and endoscopy trials to watch at ACG 2025.

ACP Releases Position Paper on Colorectal Cancer Screening, Surveillance Abigail Brooks, MA

The ACP Performance Measurement Committee reviewed 5 performance measures for CRC screening, ultimately only supporting 1 of them.

Recommended News For You

Optimizing Sequencing of BCMA-Directed Therapies in Myeloma

Mezigdomide Combinations Show Promise in Multiple Myeloma

Early Identification of Ovarian Cancer; Allergy Medicine for NSCLC? Unfavorable Development for Anti-TIGIT Medication?

Avoiding Neuropathy From Chemo; Predictive Value of Screening EKGs

Can Prior Authorization Be Better With Artificial Intelligence?

Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy

Year in Review: Multiple Myeloma

Recommended Articles For You

A Comprehensive Guide to Living with Cutaneous T Cell Lymphoma: Tips & Strategies  

Vaccines that can help prevent cancer 

A Review of Cancer Treatment Evolution Towards Stem Cells and Gene Therapy 

A Closer Look at MCV Modules: Features, Functions, and Benefits  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

FDA-approved FGFR inhibitors show promise against rare and aggressive pediatric brain tumor

2.

Base Treatment Decisions in Metastatic Breast Cancer on Presence of ESR1 Mutations

3.

An "exploding" field of antibody-drug conjugates is making progress against ovarian cancer.

4.

Certain surgical gestures during prostate removal linked to better sexual function recovery

5.

A three-quarters reduction in the risk of prostate cancer is associated with an annual increase in cardiorespiratory fitness of more than three percent.

1.

Demystifying Hematoma Rectus Sheath: Knowing the Symptoms and Causes

2.

The Importance of Maintaining Normal Calcium Levels in Your Body 

3.

The New Era of Oncology: Key Updates and Clinical Insights

4.

The Latest Research on Wiskott Aldrich Syndrome 

5.

Can Wearables and AI Become a Gamechanger for Histiocytic Cancer Detection?

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

An In-Depth Look At The Signs And Symptoms Of Lymphoma

2.

The Comprehensive Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2.

3.

Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias- The Summary

4.

CNS Clarity from Day One: Rethinking Early Diagnostic Strategies in ALK+NSCLC

5.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot